OXFORD BIOMEDICA LS-,50/ GB00BDFBVT43 /
2024-09-07 1:03:56 PM | Chg. 0.000 | Volume | Bid1:03:56 PM | Ask1:03:56 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
3.740EUR | 0.00% | - Turnover: - |
3.740Bid Size: - | 4.060Ask Size: - | 310.59 mill.EUR | - | - |
Business description
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture.
Management board & Supervisory board
CEO |
---|
John Dawson |
Management board |
Stuart Paynter, Helen Stephenson-Ellis, James Miskin, Jason Slingsby, Kyriacos Mitrophanous, Matthew Treagus, Natalie Walter, Nick Page |
Supervisory board |
Dr. Roch Doliveux, Dr. Michael Hayden, Dr. Sam Rasty, Heather Preston, John Dawson, Prof. Dame Kay Davies, Robert Ghenchev, Stuart Henderson, Stuart Paynter |
Company data
Name: | Oxford BioMedica plc |
Address: | Windrush Court, Transport Way,UK-Oxford OX4 6LT |
Phone: | +44-1865-783-000 |
Fax: | +44-1865-783-001 |
E-mail: | enquiries@oxfordbiom...a.co.uk enquiries@oxfordbiomedica.co.uk |
Internet: | https://www.oxb.com/ |
Industry: | Healthcare |
Sector: | Pharmaceutical Industry |
Sub sector: | Pharmaceuticals |
End of financial year: | 12-31 |
Free Float: | 50.20% |
IPO date: | - |
Investor relations
Name: | Catherine Isted |
IR phone: | - |
IR Fax: | - |
IR e-mail: | investor-relations@o...a.co.uk investor-relations@oxfordbiomedica.co.uk |